CEBPZ and acute myeloid leukemia: However, through long‐term follow‐up of a large number of CBF‐AML patients, it has been found that the relapse rate in this group can be as high as 40%, with a median overall survival (OS) of less than 5 years, indicating clinical and genetic heterogeneity within this subtype.4, 5, 6, 7